<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04752111</url>
  </required_header>
  <id_info>
    <org_study_id>RC3-12-2020</org_study_id>
    <nct_id>NCT04752111</nct_id>
  </id_info>
  <brief_title>Dose Esmolol Infusion Have an Adjuvant Effect to TAP Block for Pain Control in Laparoscopic Cholecystectomy.</brief_title>
  <official_title>Dose Esmolol Infusion Have an Adjuvant Effect to Transversus Abdominis Plane Block for Pain Control in Laparoscopic Cholecystectomy: A Randomized Controlled Double-blind Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Benha University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Benha University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pain after laparoscopy differs considerably from that seen after laparotomy. Laparotomy&#xD;
      results mainly in parietal pain (abdominal wall), where as Pain in laparoscopy results from&#xD;
      stretching of the intra-abdominal cavity, peritoneal inflammation, and diaphragmatic&#xD;
      irritation caused by residual carbon-dioxide in the peritoneal cavity. The transverse&#xD;
      abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves&#xD;
      supplying the anterior abdominal wall (T6 to L1). While esmolol is an ultra-short acting&#xD;
      intravenous Î²-blocker having a rapid onset and offset effect. It provides an unprecedented&#xD;
      level of tolerability and safety in the perioperative setting. When used as an adjunct, it&#xD;
      has been shown to improve the postoperative recovery by reducing postoperative pain intensity&#xD;
      and intraoperative anesthetic and opioid requirements and preventing opioid-induced&#xD;
      hyperalgesia . The mechanism of this synergistic effect is uncertain, but both&#xD;
      pharmacokinetic and pharmacodynamics interactions with anesthetic drugs have been proposed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 19, 2021</start_date>
  <completion_date type="Actual">July 20, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>pain rescue-analgesia consumption</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>. If pain score exceed 3, rescue analgesia 5 mg bolus of morphine will be administered intravenous to achieve satisfactory pain control that can be repeated every 4-6 hours.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analogue pain score</measure>
    <time_frame>every 0,2,4,6,12, up to 24 hours postoperative</time_frame>
    <description>scales from zero (no pain) to ten (unbearable pain)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraoperative hemodynamic data</measure>
    <time_frame>30 minutes after induction of anesthesia</time_frame>
    <description>mean arterial blood pressure and heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative nausea and vomiting</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>A three-point rating scale (1: no postoperative nausea and vomiting, 2: nausea without vomiting, 3: nausea with vomiting. Ondansetron 4 mg will be available if required.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>24 hours postoperative</time_frame>
    <description>using a 5-point Likert scale (1 was &quot;very unsatisfied&quot;, 2- &quot;unsatisfied&quot;, 3- &quot;unsure&quot;, 4- &quot;satisfied&quot;, and 5- &quot;very satisfied&quot;).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>Group E (esmolol infusion)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 minutes before induction of anesthesia the patients will receive a loading dose of injection esmolol 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side .</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group T (TAP block)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>10 minutes before induction of anesthesia the patients will receive a loading dose of injection 30 ml isotonic saline in the iv line, followed by an IV infusion of saline at a rate of 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>administration of a loading dose esmolol infusion 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery</description>
    <arm_group_label>Group E (esmolol infusion)</arm_group_label>
    <arm_group_label>Group T (TAP block)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ASA grade I/II patients undergoing laparoscopic cholecystectomy .&#xD;
&#xD;
          2. Age group of 18 -60 years.&#xD;
&#xD;
          3. Patients giving valid informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient refusal&#xD;
&#xD;
          2. Patients belonging to ASA grade III and grade IV .&#xD;
&#xD;
          3. Coagulation disorders.&#xD;
&#xD;
          4. Patients with known allergy to one of the used drugs.&#xD;
&#xD;
          5. Extreme obesity (BMI &gt;35)&#xD;
&#xD;
          6. Patients with cardiac, pulmonary, hepatic or renal disorders&#xD;
&#xD;
          7. Pregnancy&#xD;
&#xD;
          8. Drug abusers&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samar Rafik Mohamed Amin</name>
      <address>
        <city>Benha</city>
        <state>Qalubia</state>
        <zip>13511</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Benha University</investigator_affiliation>
    <investigator_full_name>Samar Rafik Mohamed Amin</investigator_full_name>
    <investigator_title>lecturer of anesthesia and surgical ICU</investigator_title>
  </responsible_party>
  <keyword>Esmolol infusion</keyword>
  <keyword>TAP block</keyword>
  <keyword>cholecystectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

